Mar 28, 2019
CLS Therapeutics Announces Presentation on “Targeting Tumor Heterogeneity” At The New York Academy Of Sciences

NEW YORK, March 28, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class -AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Targeting Tumor Heterogeneity” being held on May 8, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed ) encoding DNase I of the treatment of pancreatic cancer animal model.

Sep 29, 2022

NEW YORK, NY /  September 28, 2022 / CLS Therapeutics, an oncology-focused gene therapy company that utilizes Extracellular DNA and NETs as novel anticacer therapeutic targets, announces that its project entered the final of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.

Sep 09, 2020

NEW YORK, NY /  September, 2020 / CLS Therapeutics, a preclinical-stage anticancer gene therapy platform company developing novel medicines to bring the curative power of cell-free DNA destruction to patients with tumors, presented preclinical data at the annual meeting of the American Society of Clinical Oncology (ASCO).

Mar 29, 2019

NEW YORK, March 29, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class-AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Cancer Metabolism and Signaling” being held on May 9, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed ) encoding DNase I of the treatment of pancreatic cancer animal model.